Zephyr AI, a developer of AI-driven platforms for personalized cancer medicine, has expanded its real-world oncology data resources through the acquisition of Aster Insights. This move grants Zephyr access to a robust longitudinal dataset from over 400,000 consenting patients collected by the Oncology Research Information Exchange Network. Combining these datasets aims to accelerate drug development, optimize patient stratification, and improve clinical trial design and cancer care delivery.